Anti-Coronavirus [BCoV1/1] Antibody

This mouse IgG1 monoclonal antibody was raised against sucrose-gradient purified bovine coronavirus (BCV) V270 and recognizes bovine or human coronavirus OC43.

Highlights:

  • Recognizes bovine or human coronavirus OC43
  • No binding detected towards SARS-CoV-2 spike protein domains S1/S2. Please see: PDF ELISA Results
  • Suitable for ELISA, Immunofluorescence, Highly Neutralizing and HE negative applications

Coronaviruses are common viruses that affect most humans and usually cause mild to moderate upper-respiratory tract illnesses. There are four main sub-groupings of coronaviruses, known as alpha, beta, gamma, and delta. OC43 is considered a beta form of the virus.

From the laboratory of Claus-Peter Czerny, DVM, University of Göttingen.

 

Catalog Number Product DataSheet Size AVAILABILITY Price Qty
EGO012
Anti-Coronavirus [BCoV1/1] Antibody
100ug Currently unavailable
Regular Price:$355.00
On Sale:
Specifications

Product Type: Antibody
Antigen: Bovine coronavirus strain V270 (BCV V270)
Isotype: IgG1
Clonality: Monoclonal
Clone Name: Anti-BCV 1/1
Reactivity: Bovine coronavirus; human coronavirus OC43
Immunogen: Sucrose-gradient purified BCV V270
Species Immunized: Mouse
Purification Method: Protein G
Buffer: 0.1M Sodium Phosphate, pH 7.4, 0.15M NaCl, 0.05% (w/v) Sodium Azide
Tested Applications: ELISA, Immunofluorescence, highly neutralizing, HE negative
Storage: -20C
Shipped: Cold packs

Data
This antibody was tested via ELISA for reactivity towards SARS-CoV-2 spike protein domains S1/S2. No binding was observed at the concentrations tested. Please see: PDF ELISA Results.
Provider
From the laboratory of Claus-Peter Czerny, DVM, University of Göttingen.
References
  1. Czerny CP, Eichhorn W. Characterization of monoclonal and polyclonal antibodies to bovine enteric coronavirus: establishment of an efficient ELISA for antigen detection in feces. Vet Microbiol. 1989 Jun;20(2):111-22.

If you publish research with this product, please let us know so we can cite your paper.

Loading...